Immunizations and Vaccine Schedule for Seniors: Flu, Pneumonia, Shingles, and More

The immune system doesn't retire gracefully. After age 65, it becomes measurably less effective at fighting off pathogens it has encountered before — and markedly worse at responding to new ones. This page covers the core vaccines recommended for adults 65 and older, how the major ones work and differ from each other, the clinical scenarios that change which shots matter most, and the decision points where a pharmacist or physician needs to weigh in. Getting these details right isn't paperwork — it's one of the most cost-effective interventions in all of chronic condition management in senior care.

Definition and scope

Vaccine schedules for older adults are formal clinical recommendations, updated annually by the Advisory Committee on Immunization Practices (ACIP), a federal advisory body that reports to the Centers for Disease Control and Prevention. The CDC publishes the official Adult Immunization Schedule each year, and the 65-and-older cohort has a distinct column — not a footnote — because the risk calculus is genuinely different.

The biological explanation is immunosenescence: a documented age-related decline in immune function that reduces both the speed and magnitude of antibody response. It also increases susceptibility to severe complications from infections that younger adults typically shake off. Influenza, for example, accounts for roughly 90% of flu-related deaths in adults 65 and older, according to CDC estimates. That asymmetry is what drives the age-specific schedule.

The core vaccines in scope for most adults 65 and older include:

1. Influenza (flu) — annual, with high-dose or adjuvanted formulations specifically indicated for 65+
2. Pneumococcal (pneumonia) — two-vaccine series covering bacterial pneumonia strains
3. Recombinant zoster vaccine (Shingrix) — two-dose series for shingles prevention
4. Tdap/Td — tetanus, diphtheria, pertussis booster
5. COVID-19 — updated formulations recommended annually per current ACIP guidance
6. RSV vaccine — added to the adult schedule in 2023 for adults 60 and older, per CDC ACIP recommendation

This is a materially longer list than what most adults were tracking a decade ago — and most of it has real epidemiological justification behind it.

How it works

The flu vaccine for seniors deserves its own paragraph because it isn't the same product given to a 35-year-old. Standard-dose influenza vaccines produce a weaker immune response in older adults. Two formulations address this directly: Fluzone High-Dose Quadrivalent, which contains 4 times the antigen of a standard dose, and FLUAD Quadrivalent, which includes an adjuvant (MF59) that amplifies immune response. A 2017 study published in The New England Journal of Medicine found high-dose flu vaccine reduced influenza-related hospitalizations by approximately 25% compared to standard-dose in adults 65 and older.

Pneumococcal vaccination now follows a two-vaccine logic. PCV20 (Prevnar 20) or PCV15 (Vaxneuvance) covers the protein-conjugated approach that trains immune memory more effectively than the older PPSV23 (Pneumovax 23) polysaccharide vaccine. ACIP guidance as of 2022 recommends most adults 65 and older receive either PCV20 alone, or PCV15 followed by PPSV23 — a sequence that wasn't standard protocol until recently.

Shingrix, manufactured by GSK, is a recombinant subunit vaccine — meaning it uses a specific viral protein rather than a weakened live virus. Its clinical efficacy is striking: in trials, it demonstrated over 90% protection against shingles across all age groups studied, including adults over 70, according to GSK's published clinical data and CDC documentation. The prior live-attenuated vaccine (Zostavax) has been discontinued in the United States as of November 2020.

Common scenarios

A functionally healthy 65-year-old and an 80-year-old with diabetes and heart failure are both "seniors" — but their vaccine situations look different in practice.

Scenario 1: Newly turned 65, no prior pneumococcal vaccine.
ACIP recommends a single dose of PCV20, or PCV15 followed by PPSV23 at least one year later. Starting from scratch at 65 is actually the cleaner path.

Scenario 2: Adults who received PPSV23 before age 65.
This is where things get more complicated. If PPSV23 was given before 65, ACIP recommends adding PCV20 or PCV15 at least one year after that prior dose — but the sequencing depends on exactly when it was received. This scenario comes up often in skilled nursing facility care, where residents may arrive with incomplete or undocumented vaccination records.

Scenario 3: Immunocompromising conditions.
Adults with HIV, organ transplants, or conditions requiring immunosuppressive therapy follow an accelerated or expanded schedule. Shingrix is recommended even earlier — starting at 50 — for immunocompromised adults, per CDC guidance.

Scenario 4: Adults who never received Shingrix.
Anyone who had chickenpox (nearly all adults born before 1980) carries the varicella-zoster virus in latent form. Vaccination doesn't require a history of shingles to be indicated — the virus is already there.

Decision boundaries

Three questions tend to determine when a healthcare provider needs to be in the conversation rather than just a pharmacist:

• Is there an egg allergy? Most flu vaccines use egg-based manufacturing. Cell-based (Flucelvax) and recombinant (Flublok) options exist and are appropriate alternatives, but the selection isn't always obvious at a retail counter.
• Is there active immunosuppression? Certain vaccines — historically including Zostavax — were contraindicated for immunocompromised patients. Shingrix changes this, but medication interactions still warrant physician review. This intersects directly with medication management for seniors.
• Is the vaccination history incomplete or unavailable? Gaps are common when older adults transition between care settings. A senior care needs assessment is a reasonable place to surface this, but a physician can also order titer testing to check existing immunity rather than defaulting to re-vaccination.

The RSV vaccine decision is an example of shared clinical decision-making rather than a blanket recommendation: ACIP characterizes it as appropriate for adults 60 and older "using shared clinical decision-making," meaning individual health factors — including respiratory conditions and fall prevention for seniors concerns tied to illness-related deconditioning — matter to the recommendation. Adults managing care for an older parent navigating these decisions may find the family caregiver guide a useful parallel resource.